



NASDAQ : GNPX

Updated: June 2020

MANAGEMENT TEAM:

Rodney Varner, Chairman & Chief Executive Officer

Catherine Vaczy, Executive VP & Chief Strategy Officer

Michael Redman, Executive VP & Chief Operating Officer

Ryan Confer MS, Chief Financial Officer

Shannon Inman, VP of Global Clinical Operations

BOARD OF DIRECTORS:

Rodney Varner, Jose Moreno Toscano, Brent Longnecker, William Wilson, Jr.

STRATEGIC ADVISOR TO THE BOARD:

James Rothman, PhD, 2013 Nobel Prize Laureate in Medicine and Physiology

SCIENTIFIC ADVISORY BOARD:

Jack Roth, MD, FACS, Scientific Founder & Chairman

George Simon, MD, FACS

Pasi Antero Janne, MD, PhD

Tony S.K. Mok, MD

RECENT HIGHLIGHTS:

- Strengthened leadership team and Board of Directors with accomplished life science leaders.
Signed a new, exclusive worldwide patent and technology license with MD Anderson, expanding Genprex's oncology franchise.
Expanded manufacturing program for TUSC2 plasmid DNA.
Preparing for GPX-001 combination trials with Tagrisso® and Keytruda®.

KEY CLINICAL ACHIEVEMENTS:

- Data from a Phase I clinical trial show GPX-001 selectively and preferentially targets primary and metastatic tumor cells, and a Maximum Tolerated Dose was established.
Interim data from a Phase I/II trial for NSCLC showed a 78% disease control rate.
Oncoprex is shown to be synergistic with EGFR TKI targeted therapy and with anti-PD1 and CTLA-4 immunotherapies.

KEY CORPORATE ACHIEVEMENTS:

- Received Fast Track Designation for GPX-001 + Tagrisso® for NSCLC in January 2020.
Recently raised \$28 million which will support R&D efforts.
Hold extensive, worldwide patent portfolio for gene therapy technologies from MD Anderson Cancer Center and the University of Pittsburgh.

CONTACT INFORMATION:

1601 Trinity Street, Bldg. B, Suite #3.322 Austin, Texas 78712

Tel: 877-774-GNPX (4679)

Email: info@genprex.com

Web: www.genprex.com

21ST CENTURY GENE THERAPIES

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies that are designed to administer disease-fighting genes for patients with cancer and diabetes.



MARKET GAPS AND UNMET MEDICAL NEED

Genprex is working to develop new treatments for large patient populations with cancer and diabetes who currently have limited treatment options.



ONCOPREX™ NANOPARTICLE DELIVERY PLATFORM

Genprex's oncology program uses a proprietary, non-viral nanonparticle platform that delivers tumor suppressor genes that are synergistic with cancer-killing drugs.



CUTTING-EDGE RESEARCH AND DEVELOPMENT

Genprex partners with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies.

BRIDGING GAPS IN MODERN MEDICINE

ONCOLOGY

NON-SMALL CELL LUNG CANCER


- Genprex's oncology combination treatment approach utilizes targeted therapies and immunotherapies.
Planned clinical trials include combinations with osimertinib (AstraZeneca's top selling drug Tagrisso®) and pembrolizumab (Merck's top selling drug Keytruda®).
Lung cancer is the leading cause of cancer deaths.

AUTO-IMMUNE DISEASES

DIABETES

- Gene therapy drug candidate addresses Type 1 and Type 2 diabetes.
May eliminate daily burden of checking and monitoring blood glucose levels.
May eliminate the need for insulin and daily medication.
Affects 34 million people in the U.S.

R&D PIPELINE AND PATH TO APPROVAL



LEAD PRODUCT CANDIDATE GPX-001 (QUARATUSUGENE OZEPLASMID)

Genprex's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is an immunogene therapy utilizing the TUSC2 gene. Specifically designed to target cancer cells, GPX-001 works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishing pathways for apoptosis (or programmed cell death) and modulating the immune response against cancer cells.

DIABETES GENE THERAPY, GPX-002

Genprex's diabetes gene therapy, GPX-002, works to transform alpha cells in the pancreas into insulin producing beta-like cells. In vivo preclinical studies show that GPX-002 restored normal blood glucose levels for an extended period of time. A Phase I clinical trial could be the first-ever gene therapy tested in humans for diabetes.

Statements contained herein not historical in nature are "forward-looking statements" (FLS) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such FLS and include statements relating to effects of our product candidates, planned clinical trials and potential partnerships, all as more fully described in Genprex's SEC filings.